A multicentre, randomised, comparative trial to assess the tolerance (maximum well-tolerated dose), efficacy and pharmacokinetics of escalating doses of CASODEX (300 mg po daily, increasing by 150 mg intervals) versus castration (medical or surgical) in the treatment of advanced carcinoma of the prostate

Study identifier:7054IL/0009

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A multicentre, randomised, comparative trial to assess the tolerance (maximum well-tolerated dose), efficacy and pharmacokinetics of escalating doses of CASODEX (300 mg po daily, increasing by 150 mg intervals) versus castration (medical or surgical) in the treatment of advanced carcinoma of the prostate

Medical condition

prostate cancer

Phase

Phase 3

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Nov 1994

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2042&filename=CSR-7054il0009.pdf
Download
CSR-7054IL-0009.pdf
Download
Trial Results Summaries
Available here

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2042&filename=CSR-7054il0009.pdf

CSR-7054IL-0009.pdf

Trial Results Summaries